RxDoctor Payments Data

Umme Nur, MD

Internal Medicine · Marietta, GANPI 1629423298

Payments from drug & device makers

$1,906in general payments, 2019–2025

Across 92 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$321
  • Pfizer$182
  • AstraZeneca$174
  • Astellas Pharma US Inc$170
  • Lilly USA, LLC$152
  • AbbVie$113
  • plus $795 from 15 others

What the payments were for

  • Food & beverage$1,906100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,906 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$79,767
Medicare patients
265
Services billed
3,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$86,309
JardianceEmpagliflozin44$64,996
EliquisApixaban47$50,026
JanuviaSitagliptin Phosphate28$33,639
FarxigaDapagliflozin Propanediol26$31,491
MounjaroTirzepatide28$28,828
ProliaDenosumab12$20,799
XareltoRivaroxaban12$14,746
EntrestoSacubitril/Valsartan12$14,578
MyrbetriqMirabegron15$14,334
BrilintaTicagrelor11$4,816
SynthroidLevothyroxine Sodium41$3,298
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,197
SymbicortBudesonide/Formoterol Fumarate12$3,182
Atorvastatin Calcium446$3,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$321$86,30983 claims
Boehringer IngelheimJardiance$18$64,99644 claims
PfizerEliquis$182$50,02647 claims
AstraZenecaFarxiga, Brilinta, Symbicort$174$39,48949 claims
Lilly USA, LLCMounjaro$152$28,82828 claims
AmgenProlia$101$20,79912 claims
NovartisEntresto$106$14,57812 claims
Astellas Pharma US IncMyrbetriq$170$14,33415 claims
AbbVieSynthroid$113$3,29841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →